Bangkok Genomics Innovation Public Company Limited (BKGI.BK)
THB 1.99
(-1.49%)
THB 1.99
(-1.49%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | 72.47 Million | 81.17 Million | 55.63 Million | 12.65 Million |
| Net Income | 32.14 Million | 75.11 Million | 105.66 Million | 13.8 Million |
| Depreciation & Amortization | 15.96 Million | 14.53 Million | 8.48 Million | 7.58 Million |
| Deferred income taxes | -197.92 Thousand | 3.54 Million | 266.59 Thousand | -510.36 Thousand |
| Stock-based compensation | - | - | - | - |
| Change in working capital | 21.76 Million | -11.02 Million | -60.92 Million | -12.51 Million |
| Other non-cash items | 6.09 Million | 40.82 Million | 78.29 Million | 31.41 Million |
| Investing Cash Flow | -45.18 Million | -1.49 Million | -13.48 Million | -2.1 Million |
| Investments in PPE | -5.08 Million | -28.18 Million | -13.48 Million | -2.1 Million |
| Acquisitions | 5607.00 | 440.14 Thousand | - | - |
| Investment purchases | -40.1 Million | -3.5 Million | -3143.00 | -5464.00 |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | -100 Thousand | 29.74 Million | - | - |
| Financing Cash Flow | -49.65 Million | 18.05 Million | -3.25 Million | -7.72 Million |
| Debt repayment | -5.65 Million | -5.44 Million | -3.25 Million | -6 Million |
| Dividends payments | -44 Million | -166.5 Million | - | -1.72 Million |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | - | 190 Million | - | - |
| Other Financing Activities | -5.65 Million | 190 Million | - | - |
| Accounts receivables | 9.21 Million | -62.52 Thousand | -46.97 Million | -8.54 Million |
| Accounts payables | 11.87 Million | -5.37 Million | -8.05 Million | 10.46 Million |
| Inventory | 7.33 Million | -3.76 Million | -4.14 Million | -13.86 Million |
| Other working capital | -6.66 Million | -1.82 Million | -1.74 Million | -570.98 Thousand |
| Cash at beginning of period | 148.34 Million | 50.65 Million | 11.74 Million | 8.93 Million |
| Cash at end of period | 125.88 Million | 148.34 Million | 50.65 Million | 11.74 Million |
| Capital Expenditure | -5.08 Million | -28.18 Million | -13.48 Million | -2.1 Million |
| Effect of forex changes on cash | -92.44 Thousand | -42.15 Thousand | 6943.00 | -1106.00 |
| Net cash flow / Change in cash | -22.45 Million | 97.69 Million | 38.9 Million | 2.81 Million |
| Free Cash Flow | 67.38 Million | 52.99 Million | 42.15 Million | 10.54 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 13.8 Million | 9.66 Million | 32.14 Million | 2.88 Million | 15.62 Million | 75.11 Million |
| Depreciation & Amortization | 4.17 Million | 4.13 Million | 15.96 Million | 4.06 Million | 3.92 Million | 14.53 Million |
| Deferred income taxes | -23 Thousand | -18 Thousand | -197.92 Thousand | 189 Thousand | -189 Thousand | 3.54 Million |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -628 Thousand | -31.13 Million | 21.76 Million | 2.81 Million | -893 Thousand | -11.02 Million |
| Other non-cash items | 10.93 Million | 35.1 Million | 6.09 Million | 4.12 Million | 11.96 Million | 40.82 Million |
| Investing Cash Flow | -66.58 Million | -85 Thousand | -45.18 Million | -2.08 Million | -915 Thousand | -1.49 Million |
| Investments in PPE | -6.58 Million | -85 Thousand | -5.08 Million | -2.08 Million | -915 Thousand | -28.18 Million |
| Acquisitions | - | - | 5607.00 | - | - | 440.14 Thousand |
| Investment purchases | -60 Million | - | -40.1 Million | -2000.00 | - | -3.5 Million |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -59.37 Million | 352 Thousand | -100 Thousand | - | -19 Thousand | 29.74 Million |
| Financing Cash Flow | -1.4 Million | 249.81 Million | -49.65 Million | -1.46 Million | -21.46 Million | 18.05 Million |
| Debt repayment | -1.4 Million | -1.4 Million | -5.65 Million | -1.46 Million | -1.46 Million | -5.44 Million |
| Dividends payments | - | - | -44 Million | - | -20 Million | -166.5 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | -9.58 Million | 260.8 Million | - | - | - | 190 Million |
| Other Financing Activities | 1.4 Million | -1.4 Million | - | - | - | 190 Million |
| Accounts receivables | -17.96 Million | -14.98 Million | 9.21 Million | -2.08 Million | -75 Thousand | -62.52 Thousand |
| Accounts payables | 20.81 Million | -4.28 Million | 11.87 Million | -6.46 Million | 1.24 Million | -5.37 Million |
| Inventory | -4.76 Million | -6.85 Million | 7.33 Million | 11.35 Million | -2.12 Million | -3.76 Million |
| Other working capital | 1.28 Million | -5.01 Million | -6.66 Million | 24 Thousand | 69 Thousand | -1.82 Million |
| Cash at beginning of period | 359.15 Million | 147.53 Million | 148.34 Million | 147.53 Million | 148.34 Million | 50.65 Million |
| Cash at end of period | 308.61 Million | 359.15 Million | 125.88 Million | 152.85 Million | 147.53 Million | 148.34 Million |
| Capital Expenditure | -6.58 Million | -85 Thousand | -5.08 Million | -2.08 Million | -915 Thousand | -28.18 Million |
| Effect of forex changes on cash | 53 Thousand | 167 Thousand | -92.44 Thousand | 116 Thousand | -59 Thousand | -42.15 Thousand |
| Net cash flow / Change in cash | -50.53 Million | 211.62 Million | -22.45 Million | 5.32 Million | -814.39 Thousand | 97.69 Million |
| Free Cash Flow | 11.43 Million | -16.71 Million | 67.38 Million | 6.67 Million | 20.7 Million | 52.99 Million |
HAVI
CBUS
MADHUSE
NEWGEN
NGMC
VBBR3